CD19 and acute lymphoblastic leukemia: Another anti-CD19 mAb named B43 conjugated with the tyrosine kinase inhibitor (TKI) genistein has entered clinical trials in children with r/r ALL and non-Hodgkin’s lymphoma (NHL), but no results were found in the literature search.